Cidofovir dihydrate Inhibitor

Solid. Powder

99.97%

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

279.19

<1mg/ml refers to the product slightly soluble or insoluble

C8H14N3O6P

O.O.Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1

149394-66-1

EGFR kinase assays: In vitro inhibitory enzyme kinetic assays using recombinant EGFR L858R/T790M and WT protein and are performed using the ATP/NADH coupled assay system in a 96-well format. WZ4002 is added to determine its inhibitory effects.

Cidofovir (5mg/kg/day) subcutaneously for 5 days significantly reduces average virus infectivity titer in blood, spleen, lung and salivary gland in infected guinea pigs. Cidofovir significantly reduces lymphocytosis and average tissue indexe of spleen in infected animals. [2]. Cidofovir suppresses all manifestations (skin lesions, paralysis of the hind legs, and mortality) of hairless mice infected intracutaneously with HSV-1 or HSV-2. The most remarkable feature of Cidofovir is that a single administration of the compound, even as late as 4 days after infection, conferees significant protection against HSV-1 or HSV-2 infection. [4] Cidofovir inhibits growth of the highly aggressive melanoma tumor arising from mouse melanoma B16 cells grafted subcutaneously in C57B16/J mice. [5]